TrialBlood cancer journal2019

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

Marinus van Oers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.